Review decision – October 2020
Decision that the existing guidance remains unchanged
We would like to update you on the decision made regarding the review of the existing guidance on TA414; Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma.
Stakeholders were asked to inform NICE as to whether they believed that the guidance remains relevant or whether there is an evidence based case for updating the existing recommendations.
Based on the information received, NICE does not believe that an update of the guidance is required at this time. The guidance will therefore remain unchanged, in its current form, unless or until NICE becomes aware of substantive information which would make it reconsider.
This page was last updated: